Harapriya Mohapatra

Dr. Harapriya Mohapatra


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2017 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
SSSantosh Kumar Singh
Santosh Kumar Singh
RERoseleen Ekka
Roseleen Ekka
MMMitali Mishra
Mitali Mishra
HMHarapriya Mohapatra
Harapriya Mohapatra

4 May 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
MMMitali Mishra
Mitali Mishra
SKSatish Kumar
Satish Kumar
RMRakesh K. Majhi
Rakesh K. Majhi
LGLuna Goswami
Luna Goswami
CGChandan Goswami
Chandan Goswami
HMHarapriya Mohapatra
Harapriya Mohapatra
Antibacterial therapy is of paramount importance in treatment of several acute and chronic infectious diseases caused by pathogens. Over the years extensive use and misuse of antimicrobial agents has led to emergence of multidrug resistant (MDR) and extensive drug resistant (XDR) pathogens. This drastic escalation in resistant phenotype has limited the efficacy of available therapeutic options. Thus, the need of the hour is to look for alternative therapeutic approaches to mitigate healthcare concerns caused due to MDR bacterial infections. Nanoparticles have gathered much attention as potential candidates for antibacterial therapy. Equipped with advantages of, wide spectrum bactericidal activity at very low dosage, inhibitor of biofilm formation and ease of permeability, nanoparticles have been considered as leading therapeutic candidates to curtail infections resulting from MDR bacteria. However, substrate non-specificity of efflux pumps, particularly those belonging to resistance nodulation division super family, have been reported to reduce efficacy of many potent antibacterial therapeutic drugs. Previously, we had reported antibacterial activity of polysaccharide-capped silver nanoparticles (AgNPs) toward MDR bacteria. We showed that AgNPs inhibits biofilm formation and alters expression of cytoskeletal proteins FtsZ and FtsA, with minimal cytotoxicity toward mammalian cells. In the present study, we report no reduction in antibacterial efficacy of silver nanoparticles in presence of AcrAB-TolC efflux pump proteins. Antibacterial tests were performed according to CLSI macrobroth dilution method, which revealed that both silver nanoparticles exhibited bactericidal activity at very low concentrations. Further, immunoblotting results indicated that both the nanoparticles modulate the transporter AcrB protein expression. However, expression of the membrane fusion protein AcrA did show a significant increase after exposure to AgNPs. Our results indicate that both silver nanoparticles are effective in eliminating MDR Enterobacter cloacae isolates and their action was not inhibited by AcrAB-TolC efflux protein expression. As such, the above nanoparticles have strong potential to be used as effective and alternate therapeutic candidates to combat MDR gram-negative Enterobacterial pathogens.

1 September 2017 in Microbial Pathogenesis
Verified
Journal Article
Closed access
SSSantosh Kumar Singh
Santosh Kumar Singh
MMMitali Mishra
Mitali Mishra
MSMinu Sahoo
Minu Sahoo
SPShashank Patole
Shashank Patole
SSSuneeta Sahu
Suneeta Sahu
HMHarapriya Mohapatra
Harapriya Mohapatra


1 January 2017 in Microbial Pathogenesis
Verified
Journal Article
Closed access
SSSantosh Kumar Singh
Santosh Kumar Singh
MMMitali Mishra
Mitali Mishra
MSMinu Sahoo
Minu Sahoo
SPShashank Patole
Shashank Patole
HMHarapriya Mohapatra
Harapriya Mohapatra

8 January 2021
Verified
Book Chapter
Closed access
PDF file
MMMitali Mishra
Mitali Mishra
SPShashank Patole
Shashank Patole
HMHarapriya Mohapatra
Harapriya Mohapatra